Cancer Type: Malignant Hematology
Study Type: Treatment
Phase: Phase I
Principal Investigator: Sallman, David
A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation, With a Substudy in Subjects With Relapsed or Refractory Myelodysplastic Syndrome and a Substudy in Subjects With Advanced Hematologic Malignancies With Organ Impairment
The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Dose Escalation and Expansion Objectives: Primary: To assess the safety and tolerability of treatment with AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle in subjects with advanced hematologic malignancies. The initial dosing regimen was twice daily (approximately every 12 hours). Based on the emerging data, a once daily (approximately every 24 hours) dosing schedule has been implemented. Alternative dosing schedules, including administration of the same total daily dose using different dosing schedules in concurrent cohorts, may be explored as agreed upon by the Clinical Study Team. To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of AG-120 in subjects with advanced hematologic malignancies. To assess the clinical activity of AG-120 in subjects with relapsed and/or refractory (R/R) acute myelogenous leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation who are enrolled in Arm 1 of the expansion phase. Secondary: To describe the dose-limiting toxicities (DLTs) of AG-120 in subjects with advanced hematologic malignancies. To characterize the pharmacokinetics (PK) of AG-120 in subjects with advanced hematologic malignancies. To evaluate the PK/pharmacodynamic (PD) relationship of AG-120 and 2-hydroxygluturate (2-HG). To characterize the clinical activity associated with AG-120 in subjects with advanced hematologic malignancies. Exploratory: To characterize the PD effects of AG-120 in subjects with advanced hematologic malignancies by the assessment of: Changes in the patterns of cellular differentiation of IDH1-mutated and wild type cells. Changes in histone and deoxyribonucleic acid (DNA) methylation profiles in IDH1-mutated and wild type cells. To evaluate gene mutation status, global gene expression profiles, and other potential prognostic markers (cytogenetics) in IDH1-mutated cells and plasma, as well as subclonalpopulations of non-IDH1-mutated cells, to explore predictors of antitumor activity and/or resistance. To evaluate changes in the metabolic profiles in IDH1-mutated and wild type cells, urine and plasma. To monitor plasma cholesterol and 4â-OH-cholesterol levels as a potential cytochrome P450 (CYP) 3A4 induction marker for subjects enrolled in the dose escalation phase. MDS Substudy Objectives: Primary: To assess the safety and tolerability of treatment with AG-120 administered as 500 mg once daily (QD) dosed orally on Days 1 to 28 of a 28-day cycle in subjects with R/R myelodysplastic syndrome (MDS). To assess the clinical activity of AG-120 in subjects with R/R MDS. Secondary: To characterize the PK of AG-120 in subjects with R/R MDS. To evaluate the PK/PD relationship of plasma AG-120 and 2-HG. Organ Impairment Substudy Objectives: Primary: To assess the PK of AG-120 administered at 500 mg QD in subjects with IDH1-mutated hematologic malignancies with moderate hepatic impairment, severe hepatic impairment, or severe renal impairment compared with subjects with IDH1-mutated hematologic malignancies with adequate hepatic and renal function.
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
A secure website for patients to access their medical care at Moffitt.
An online resource for referring physicians and their staff.
For Moffitt faculty & staff members to access MoffittNet applications.
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday